<DOC>
	<DOCNO>NCT01284309</DOCNO>
	<brief_summary>The purpose study ass affect mirabegron intraocular pressure ( IOP ) healthy subject .</brief_summary>
	<brief_title>A Study Assess Intraocular Pressure Ocular Safety Beta-3 Agonist Mirabegron Research Subjects</brief_title>
	<detailed_description />
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Female subject must either postmenopausal ( define least 2 year without menses ) surgically sterile ( least 1 month ) childbearing potential contraception . All woman childbearing potential require use contraception consist two form birth control ( one must barrier method ) , must lactate , must breastfeed study period 30 day final study drug administration . All woman childbearing potential must negative urine pregnancy test Male subject female spouses/partners childbearing potential must use contraception consist two form birth control ( one must barrier method ) study period Subject may either otherwise healthy symptom overactive bladder selfreport History glaucoma ocular hypertension Abnormal visual field either eye Ophthalmic condition would interfere reliable Goldmann tonometry ( e.g. , corneal edema , uveitis , severe keratoconjunctivitis sicca ) History major ocular infection , inflammation , herpes simplex keratitis ; evidence current clinically significant blepharitis conjunctivitis Any history ocular surgery include refractive surgery laserassisted situ keratomileusis ( LASIK ) photorefractive keratectomy ( PRK ) eye Ocular trauma within past six month Severe myopia Diabetes , Type I Type 2 , without medical management Cardiovascular disease require pharmacotherapy History type dysrhythmia Systemic hypertension require pharmacotherapy Past diagnosis connective tissue autoimmune disease include rheumatoid arthritis spondyloarthropathies History psychiatric illness require hospitalization Recent history ( within past 24 month ) alcohol substance abuse ( exception nicotine ) Used tobaccocontaining product nicotinecontaining product within past 3 month Has part clinical study past within 30 day currently take part clinical study present study , participate previous study mirabegron time Ocular medication kind within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Intraocular Pressure ( IOP )</keyword>
	<keyword>YM178</keyword>
</DOC>